Read More

IGM Biosciences Announces Strategic Pipeline Prioritization And Cash Runway Extension; Cash Runway Expected To Extend Into Q2 2026; Reduction In Workforce Of Approximately 22%

– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease –– Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease –– All clinical development in

IGMS

Read More

AT&T CEO John Stankey Updates Shareholders At The 2023 UBS Global Media & Communications Conference; Says On Track For 2023 Full-Year Free Cash Flow Of About $16.5B; Expects 2024 Capital Investment In The $21B-22B Range

As part of AT&T's multiyear strategy to drive sustainable and profitable growth, the company detailed how it will accelerate network innovation, efficiency and structural cost improvement across the largest wireless

T